Department of Internal Medicine, Bronx Lebanon Hospital Center, Albert Einstein College of Medicine, Bronx, New York, USA.
Clin Cardiol. 2011 Sep;34(9):528-31. doi: 10.1002/clc.20928. Epub 2011 Jun 29.
Gastrointestinal (GI) bleeding is a serious complication associated with use of antiplatelet therapy, and proton pump inhibitors (PPIs) are known to be beneficial in decreasing such risk. Several studies in the recent past have suggested concerns regarding interaction between clopidogrel and PPIs, presumably due to inhibition of clopidogrel activity and thus attenuation of its antiplatelet activity. A web-based literature and guidelines search was done using the keywords "clopidogrel," "omeprazole," "proton pump inhibitors" and "interaction." Of the available results, relevant studies (n = 11) were then systematically reviewed and summarized. The studies were categorized based on their retrospective or prospective nature. Most of the retrospective, observational studies suggested a link between the 2; however, recent prospective studies have shown no interaction, as well as a positive influence of PPIs in preventing the GI side effects of antiplatelet therapy. There is currently insufficient clinical evidence to suggest interaction between clopidogrel and PPIs and decision to add PPI therapy to clopidogrel should be guided by its clinical indications rather than as a routine prophylactic measure.
胃肠道出血是抗血小板治疗相关的严重并发症,质子泵抑制剂(PPIs)已被证实可降低此类风险。过去的几项研究表明,氯吡格雷和 PPIs 之间可能存在相互作用的担忧,推测是由于氯吡格雷活性受到抑制,从而减弱了其抗血小板活性。使用关键词“氯吡格雷”、“奥美拉唑”、“质子泵抑制剂”和“相互作用”,在网络上进行了文献和指南搜索。对可用的结果进行筛选,然后系统地回顾和总结了相关研究(n=11)。这些研究根据其回顾性或前瞻性进行了分类。大多数回顾性观察性研究表明两者之间存在关联;然而,最近的前瞻性研究表明两者之间没有相互作用,并且 PPI 可积极预防抗血小板治疗的胃肠道副作用。目前,临床证据不足,不能表明氯吡格雷和 PPIs 之间存在相互作用,添加 PPI 治疗应根据其临床适应证来决定,而不是作为常规预防措施。